NIFK

Across TCGA pan-cancer cohorts, NIFK Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NIFK data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher NIFK Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NIFK expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, LIHC, and BLCA are the cancer types where NIFK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.180	0.796	.001	30	view →
LIHC	OS	Median	All	0.079	0.774	<.001	18	view →
BLCA	OS	Median	All	0.392	0.722	.002	16	view →
UCEC	DFS	Median	II,III,IV	1.000	0.439	.018	14	view →
ESCA	OS	Median	All	0.196	0.704	<.001	12	view →
COAD	OS	Median	All	0.168	0.805	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NIFK–KIRC (DFS)

Open the KIRC breakdown →